TW200500070A - Method of improved diuresis in individuals with impaired renal function - Google Patents

Method of improved diuresis in individuals with impaired renal function

Info

Publication number
TW200500070A
TW200500070A TW093111522A TW93111522A TW200500070A TW 200500070 A TW200500070 A TW 200500070A TW 093111522 A TW093111522 A TW 093111522A TW 93111522 A TW93111522 A TW 93111522A TW 200500070 A TW200500070 A TW 200500070A
Authority
TW
Taiwan
Prior art keywords
individuals
renal function
impaired renal
diuresis
improved
Prior art date
Application number
TW093111522A
Other languages
English (en)
Chinese (zh)
Inventor
Howard C Dittrich
Kenneth J Widder
Lauren Otsuki
Roland Blantz
Scott Thomson
Original Assignee
Novacardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacardia Inc filed Critical Novacardia Inc
Publication of TW200500070A publication Critical patent/TW200500070A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW093111522A 2003-04-25 2004-04-23 Method of improved diuresis in individuals with impaired renal function TW200500070A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46600703P 2003-04-25 2003-04-25

Publications (1)

Publication Number Publication Date
TW200500070A true TW200500070A (en) 2005-01-01

Family

ID=33418325

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093111522A TW200500070A (en) 2003-04-25 2004-04-23 Method of improved diuresis in individuals with impaired renal function

Country Status (16)

Country Link
US (3) US7579331B2 (OSRAM)
EP (1) EP1620107A1 (OSRAM)
JP (1) JP2006524699A (OSRAM)
KR (1) KR20060004959A (OSRAM)
CN (1) CN1859913A (OSRAM)
AR (1) AR044069A1 (OSRAM)
AU (1) AU2004233852A1 (OSRAM)
BR (1) BRPI0409699A (OSRAM)
CA (1) CA2522971A1 (OSRAM)
MX (1) MXPA05011371A (OSRAM)
NO (1) NO20055536L (OSRAM)
NZ (1) NZ543109A (OSRAM)
RU (1) RU2367442C2 (OSRAM)
TW (1) TW200500070A (OSRAM)
WO (1) WO2004096228A1 (OSRAM)
ZA (1) ZA200509311B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
AU2004233852A1 (en) 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
JP2007504136A (ja) * 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法
JP2007532671A (ja) * 2004-04-16 2007-11-15 ノヴァカーディア，インク． アデノシンａ１受容体アンタゴニストおよびアルドステロン阻害剤を含む併用療法
WO2006091716A2 (en) * 2005-02-24 2006-08-31 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
CN101166515A (zh) * 2005-04-22 2008-04-23 美国诺华卡迪亚公司 用于非水溶性药物成分静脉注射的乳剂的生产
JPWO2007069675A1 (ja) * 2005-12-14 2009-05-28 協和発酵キリン株式会社 キサンチン誘導体の易吸収性経口製剤
CA2648281A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
WO2007149283A2 (en) * 2006-06-16 2007-12-27 Novacardia, Inc. Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416810C (sv) 1977-10-14 1982-07-19 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
FR2531085A1 (fr) 1982-07-28 1984-02-03 Adir Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4769377A (en) 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
DE8817122U1 (de) 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
SE9000207L (sv) 1990-01-22 1991-07-23 Nobel Chemicals Ab Laekemedel samt anvaendningen av detsamma
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
WO1993000081A1 (en) 1991-06-28 1993-01-07 Sepracor, Inc. Optically pure s(-) nadolol for treatment of cardiovascular disorders
CA2093403C (en) 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
TW252044B (OSRAM) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
DE4238367A1 (de) 1992-11-13 1994-05-19 Boehringer Ingelheim Kg Diuretisches Mittel
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
CN1049117C (zh) 1994-09-16 2000-02-09 赵明玉 预防和治疗偏头痛的偏头痛片
WO1997004782A1 (en) 1995-07-26 1997-02-13 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion or solid dispersion preparation of xanthine derivatives
ES2232877T3 (es) 1996-08-07 2005-06-01 Kyowa Hakko Kogyo Co., Ltd. Emulsion grasa que contiene un derivado de xantina.
US6187780B1 (en) 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
DE19816857A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20020115687A1 (en) 1998-04-24 2002-08-22 Evan Beckman Method and composition for restoring diuretic and renal function
AU3757999A (en) 1998-04-24 1999-11-16 Biogen, Inc. Adenosine a1 receptor antagonist containing composition and method for restoringdiuretic and renal function
EP0970696A1 (en) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
CA2390496A1 (en) 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists
PL198156B1 (pl) 1999-11-12 2008-05-30 Biogen Idec Ma Ksantyny podstawione w pozycji 8, sposób ich wytwarzania i ich zastosowanie oraz kompozycja farmaceutyczna
US20050038017A1 (en) 1999-12-22 2005-02-17 Wolff Andrew A. Method and composition for restoring diuretic and renal function
UA75625C2 (en) 2000-12-01 2006-05-15 Biogen Inc Condensed purine derivatives as a1 adenosine receptor antagonists
MXPA03005462A (es) 2000-12-18 2003-09-25 Novartis Ag Combinacion terapeutica de amlodipina y benazepril.
UA80258C2 (en) 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
US20040229901A1 (en) 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
AU2004233852A1 (en) 2003-04-25 2004-11-11 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US20060293312A1 (en) 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
US20050070524A1 (en) 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
JP2007532671A (ja) 2004-04-16 2007-11-15 ノヴァカーディア，インク． アデノシンａ１受容体アンタゴニストおよびアルドステロン阻害剤を含む併用療法
CA2565037A1 (en) 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
CA2648281A1 (en) 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
EP2035009A1 (en) 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
WO2007149283A2 (en) 2006-06-16 2007-12-27 Novacardia, Inc. Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
CA2661044A1 (en) 2006-08-22 2008-02-28 Novacardia, Inc. Kw-3902 conjugates that do not cross the blood-brain barrier

Also Published As

Publication number Publication date
NZ543109A (en) 2008-06-30
CA2522971A1 (en) 2004-11-11
US7579331B2 (en) 2009-08-25
KR20060004959A (ko) 2006-01-16
US20060035911A1 (en) 2006-02-16
WO2004096228A1 (en) 2004-11-11
ZA200509311B (en) 2006-10-25
AR044069A1 (es) 2005-08-24
RU2005131938A (ru) 2006-06-27
MXPA05011371A (es) 2005-12-01
JP2006524699A (ja) 2006-11-02
AU2004233852A1 (en) 2004-11-11
US20050004145A1 (en) 2005-01-06
US20060030572A1 (en) 2006-02-09
EP1620107A1 (en) 2006-02-01
NO20055536D0 (no) 2005-11-23
RU2367442C2 (ru) 2009-09-20
NO20055536L (no) 2005-12-29
CN1859913A (zh) 2006-11-08
BRPI0409699A (pt) 2006-04-18

Similar Documents

Publication Publication Date Title
WO2007149285A3 (en) Method of improved diuresis in individuals with impaired renal function
MXPA05011371A (es) Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
WO2003026591A3 (en) Modification of feeding behavior
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
EP1513825A4 (en) ANTITU-CULINARY MEDICAMENT: COMPOSITIONS AND METHODS
DK1663229T3 (da) Farmaceutiske kombinationer af hydrocodon og naltrexon
CY1108918T1 (el) Φαρμακευτικοι συνδυασμοι οξυκωδονης και ναλοξονης
AU2003243551A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
WO2004000354A3 (en) Method of treating the syndrome of lipodystrophy
AR042534A1 (es) Formas de dosificacion que comprenden un inhibidor de la proteina de transferencia de esteres de colesterilo (ptec) y un inhibidor de la 3-hidroxi-3-metil glutaril-coenzima a (hmg-co-a) reductasa
FR2850377B1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
WO2004012762A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
FR2873690B1 (fr) Derives d'oxopiperidine, leur preparation et leur application en therapeutique
AU2003255463A1 (en) Substituted isoxazole derivatives and their use in pharmaceutics
GB0201367D0 (en) Composition
EP1482937A4 (en) NEW TYLOINDICINE AND RELATED METHOD, PHARMACEUTICAL COMPOSITIONS AND METHOD
AU2003238242A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
CY1109215T1 (el) Συστημα χορηγησης οπιοειδους
AU2003211630A1 (en) Cigarette reduced in the amount of sub-stream smoke
EA200500175A1 (ru) Соль морфин-6-глюкуронида
FR2842527B1 (fr) Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique
AU2003221289A1 (en) An artificial low toxicity tobacco base and a method using the tobacco base
FR2865207B1 (fr) Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
RU2002113945A (ru) Способ создания "новокаиновой подушки" для микросклерозирования
AU2003261011A1 (en) Combined casual and training footwear